Clinical trial NCT02619097: Safety & Pharmacokinetics of Pegolsihematide for Treatment of Anemia Patient With Myelodysplastic Syndromes
Official title: Safety & Pharmacokinetics of Pegolsihematide for Treatment of Anemia Patient With Myelodysplastic Syndromes
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
Conditions: Myelodysplastic Syndromes
Anemia
Lead sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2015-12-02
Enrollment: 24
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The primary objectives of the trial are to assess the safety and pharmacokinetics profile of pegolsihematide for treatment of anemia patient with myelodysplastic syndromes.

Detailed description: The study started from the lowest dose, 0.08mg/kg, each group will enroll 4 to 6 subjects.

Eligibility criteria: Inclusion Criteria:

1. Men or women ≥18 years, premenopausal women must have negative pregnancy test.
2. Documented diagnosis of myelodysplastic syndromes (MDS) according to World Health Organization (WHO) criteria, including refractory anemia (RA), refractory anemia with ringed sideroblasts (RARS), refractory cytopenia with multilineage dysplasia (RCMD), MDS-U, 5q-.
3. Meets International Prognostic Scoring System (IPSS) classification of low or intermediate-1 risk disease as determined by microscopic and standard cytogenetic analysis of the bone marrow during screening.
4. Never with erythropoietin agents treatment prior to enrollment.
5. Eastern cooperative oncology group (ECOG) performance status of 0 or 1 during screening.
6. Hemoglobin ≥7g/dL and ≤10g/dL, at least two detections during screening.
7. Adequate transferrin saturation (≥15%), ferritin (≥12ng/mL), folate (≥ lower limits of normal), vitamin B12 (≥ lower limits of normal)
8. Patients understand and are able to provide written informed consent.

Exclusion Criteria:

1. Pregnant or breast feeding women or women having positive pregnant test, women or men whose spouse plan to become pregnant with 4 weeks after the end of treatment .
2. Therapy-related or secondary MDS.
3. Previously diagnosed with intermediate-2 or high risk MDS per International Prognostic Scoring System (IPSS).
4. History of severe allergic or anaphylactic reactions or hypersensitivity to erythropoiesis-stimulating agents or polyethylene glycol.
5. History of red blood cell or blood transfusion during 4 weeks prior to enrollment.
6. Known other disease which can lead to anemia (including haemolytic disease and digestive tract hemorrhage).
7. Uncontrolled hypertension 2 weeks prior to enrollment, defined as systolic blood pressure ≥160mmHg or diastolic blood pressure ≥ 95mmHg.
8. Clinically significant systemic infection or uncontrolled chronic inflammatory disease (ie, rheumatoid arthritis, inflammatory bowel disease) as determined by the investigator at screening.
9. Evidence of bone marrow collagen fibrosis, biopsy argentaffin staining showed reticular fiber ≥＋＋.
10. History of deep venous thrombosis or arterial embolism within 12 months prior to enrollment.
11. History of cardiocerebrovascular events within 6 months prior to enrollment, include local ischemia, embolism, cerebral hemorrhage, transient ischemic attack, myocardial ischemia or other arterial thrombosis.
12. Any serious medical condition, lab abnormality or psychiatric illness within 6 months prior to enrollment.
13. History of malignancies other than curatively treated non-melanoma skin or in situ carcinoma.
14. Estimated survival time \< 6 months.
15. Plan to get major surgery which will lead to massive bleeding during the study.
16. Treatment with any other investigational drug within 6 weeks prior to enrollment, or plan to participate in any other investigational drug during the study.
17. Any other condition not specifically noted above which, in the judgement of the investigator, would preclude the patient from participating in the study.

Primary outcomes:
measure: Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
timeFrame: 28 days after injection
measure: Maximum Plasma Concentration [Cmax]
timeFrame: 10min before injection to 336h after injection
measure: Time to Maximum Plasma Concentration [Tmax]
timeFrame: 10min before injection to 336h after injection
measure: Half-life [t1/2]
timeFrame: 10min before injection to 336h after injection
measure: Area Under the Curve [AUC]).
timeFrame: 10min before injection to 336h after injection
Secondary outcomes:
measure: The changes of hemoglobin (g/L) after treatment
timeFrame: From date of recruitment until the date of biggest documented progression up to 28 weeks
measure: The changes of reticulocyte (10^9/L) after treatment
timeFrame: From date of recruitment until the date of biggest documented progression up to 28 weeks
Other outcomes:
Locations:
city: Tianjin
country: China
facility: Hospital of Blood Diseases, Chinese Academy of Medical Sciences
Study officials:
affiliation: Hospital of Blood Diseases, Chinese Academy of Medical Sciences
name: Zhijian Xiao, Doctor
role: STUDY_CHAIR
References: